Skip to main content

Table 2 Disease control rate and overall response rate according to RECIST Criteria V 1. 1

From: Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center

Characteristic

ORR

DCR

No/total

%

P value*

No/total

%

P value*

Chemosensitivity

  

.002

  

.001

 Chemosensitive tumors

6/14

42.9

 

12/14

85.7

 Chemoresistant tumors

1/25

4.0

 

8/25

32.0

Number of prior lines

     

.023

 Two lines

5/13

38.5

.018

10/13

76.9

 More than two lines

2/26

7.7

 

10/26

38.5

Age (years)

    

51.7

.925

 ˂ 50 years

5/29

17.2

.845

15/29

50.0

 ≥ 50 years

2/10

20.0

 

5/10

 

Menopausal status

   

6/13

46.2

.651

 Pre/perimenopausal

5/26

19.2

.768

14/26

53.8

 Postmenopausal

2/13

15.4

   

ECOG PS

   

5/11

54.5

.798

 0, I

1/11

9.1

.649

14/28

50.0

 II

6/28

21.4

   

Pathological type

   

16/34

52.9

.351

 IDC

5/34

14.7

.084

1/4

25.0

 ILC

1/4

25.0

 

1/1

100.0

 Others

1/1

100.0

   

Tumor grade

   

17/33

51.5

.946

 Grade I or II

6/33

18.2

.929

3/6

50.0

 Grade III

1/6

16.7

   

Type of metastasis

   

6/8

75.0

.132

 Denovo MBC

2/8

25.0

.617

14/31

45.2

 Recurrent MBC

5/31

16.1

   

No of metastasized organ/s

   

2/5

40.0

.676

 One

1/5

20.0

.898

17/34

50.0

 Two or more

6/34

17.6

   
  1. *P value calculated by Pearson chi-square test or Fisher’s exact test when appropriate though crosstabulation
  2. Abbreviations: CR complete response, DCR disease control rate, ORR overall response rate, PR partial response, RECIST response evaluation criteria in solid tumors, SD stable disease